<DOC>
	<DOCNO>NCT02466243</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability efficacy JBT-101 adult subject skin-predominant , dermatomyositis ( DM ) refractory least 3 month treatment hydroxychloroquine .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy JBT-101 Subjects With Dermatomyositis</brief_title>
	<detailed_description>Part A : An interventional , double-blind , randomize , placebo-control design use test JBT-101 22 eligible male female subject ≥ 18 ≤ 70 year age moderate-to-severely active skin-predominant dermatomyositis . Part B : A one-year open-label design test JBT-101 subject complete Part A without permanent discontinuation study product safety tolerability reason .</detailed_description>
	<mesh_term>Dermatomyositis</mesh_term>
	<criteria>Inclusion Criteria ( Part A ) : CDASI activity score ≥ 14 ; No difficulty lift walking , 1.5 x upper limit normal creatine phosphokinase aldolase ; Failed least 3 month treatment hydroxychloroquine ; Stable treatment dermatomyositis least 28 day Visit 1 ( Day 1 ) . Inclusion Criteria ( Part B ) : Completion dose Part A without permanent discontinuation stuidy product safety tolerability reason Exclusion Criteria ( Part A B ) : Significant disease condition DM may influence response study product safety ; Any one following value laboratory test Screening : 1 . A positive pregnancy test ( Visit 1 ) ; 2 . Hemoglobin &lt; 10 g/dL ; 3 . Neutrophils &lt; 1.0 x 10^9/L ; 4 . Platelets &lt; 75 x 10^9/L ; 5 . Creatinine clearance &lt; 50 ml/min accord modify CockcroftGault equation ; 6 . Aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase &gt; 2.5 x upper normal limit ; 7 . Total bilirubin ≥ 1.5 x upper limit normal . Any condition , opinion Principal Investigator , clinically significant may put subject great safety risk , influence response study product , interfere study assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>